/
Other
Concentration
22
Pipeline Programs↗
22
Active Trials↗
47
Companies Involved↗
Concentration is an emerging landscape with 22 programs across 47 companies. The most active players are AstraZeneca, Qilu Pharmaceutical Co., Ltd.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Raltegravir
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Voriconazole
Prism Pharmaceuticals
Methotrexate,calcium Folinate
Tianjin Medical University Cancer Institute and Hospital
Children Receiving Sevoflurane
Yeungnam University College of Medicine
Biological Data
University Hospital, Bordeaux
Phase 13
Phase 2
No programs
Phase 33
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
14 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.
Analysis
Trial Status
325
clinical trials
Completed239 · 74%
Unknown status32 · 10%
Terminated20 · 6%
Recruiting13 · 4%
Withdrawn11 · 3%
Active, not recruiting5 · 2%
Other5 · 2%
Clinical Trials
Trial Activity
325 trials
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Recruiting·—·Phase 4·NCT06119061·20 enrolled
The Effects of Various Concentrations of Ropivacaine on the Onset and Duration of Ankle Blocks
Recruiting·—·N/A·NCT06185608·174 enrolled
Chest CT Using Low-concentration Iodine Contrast Media
Recruiting·—·Phase 4·NCT05967117·370 enrolled
Page 1 of 22
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)